Business
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Topline data is on track for anticipated readout in the summer of 2026WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the completion of enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial. This trial is evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when
About this update from Sionna Therapeutics, Inc.
[{"type":"image","alt":"Sionna Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Sionna Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/COfkmNe0HLR2vVwmA9j4RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/9f8d8c0e203777999006c0b8c8d0c418","width":300,"height":300}},"lazy":false},{"type":"text","content":"Topline data is on track for anticipated readout in the summer of 2026","length":70,"tagName":"p"},{"type":"text","content":"WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF), today announced the completion of enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial. This trial is evaluating SION-719, a first-in-class nucleotide binding domain 1 (NBD1) stabilizer, when added to Trikafta® (elexacaftor/tezacaftor/ivacaftor), the current standard of care (SOC) in CF. Sionna anticipates data from the PreciSION CF trial in the summer of 2026.","length":602,"tagName":"p"},{"type":"text","content":"“Completion of enrollment in our PreciSION CF proof-of-concept trial represents a significant milestone for both Sionna and the cystic fibrosis community,” said Charlotte McKee, M.D., Chief Medical Officer of Sionna. “This is the first clinical trial evaluating an NBD1 stabilizer in people with CF, marking an important step toward directly addressing the underlying defect of the most common CF-causing mutation. We are thankful to the patients, investigators, and the broader CF community for their strong engagement as we advance this trial. We remain focused on executing and look forward to our first data readout in CF patients this summer.”","length":648,"tagName":"p"},{"type":"text","content":"The PreciSION CF Phase 2a trial (NCT07108153) is a randomized, double-blind, placebo-controlled, crossover POC study that enrolled adult CF patients homozygous for F508del on a stable dose of physician-prescribed Trikafta. The objectives of the trial are to evaluate the safety, tolerability, and pharmacokinetics of SION-719 when administered with ...